risperidone has been researched along with Constriction, Pathologic in 1 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Constriction, Pathologic: The condition of an anatomical structure's being constricted beyond normal dimensions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 9.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| "Our previous study suggested that a combination of ulinastatin and risperidone reduced post-ERCP pancreatitis (PEP) compared with ulinastatin alone." | 5.17 | Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial. ( Akiyama, D; Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Nakajima, K; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Tsujino, T; Uchino, R; Yagioka, H; Yamamoto, N; Yanagihara, Y, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uchino, R | 1 |
| Isayama, H | 1 |
| Tsujino, T | 1 |
| Sasahira, N | 1 |
| Ito, Y | 1 |
| Matsubara, S | 1 |
| Takahara, N | 1 |
| Arizumi, T | 1 |
| Toda, N | 1 |
| Mohri, D | 1 |
| Togawa, O | 1 |
| Yagioka, H | 1 |
| Yanagihara, Y | 1 |
| Nakajima, K | 1 |
| Akiyama, D | 1 |
| Hamada, T | 1 |
| Miyabayashi, K | 1 |
| Mizuno, S | 1 |
| Kawakubo, K | 1 |
| Kogure, H | 1 |
| Sasaki, T | 1 |
| Yamamoto, N | 1 |
| Nakai, Y | 1 |
| Hirano, K | 1 |
| Tada, M | 1 |
| Koike, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000459] | Phase 3 | 0 participants | Interventional | 1986-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for risperidone and Constriction, Pathologic
| Article | Year |
|---|---|
Results of the Tokyo trial of prevention of post-ERCP pancreatitis with risperidone-2: a multicenter, randomized, placebo-controlled, double-blind clinical trial.
Topics: Adult; Aged; Ampulla of Vater; Amylases; Bile Ducts, Intrahepatic; C-Reactive Protein; Cholangiopanc | 2013 |